Search - tctmd.com

Displaying 21 - 40 of 174

Sort: Relevancy | Date

Presentation TCT 2025

Cath Lab Economics 101: Understanding RVUs, DRGs, and Payer Trends

Presenter: Partha Sardar

October 26, 2025

Presentation TCT 2025

Predictors of a Positive Treadmill Stress Test in Patients with Asymptomatic Severe Aortic Stenosis: Insights from the EARLY TAVR Treadmill Registry

Presenter: Philippe Genereux

October 25, 2025

Presentation TCT 2025

Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Women with Severe Aortic Stenosis: The RHEIA Trial

Presenter: Philippe Pibarot

October 25, 2025

Presentation TCT 2025

Thirty-Day and One-Year Outcomes of the Navitor TAVR System in Patients with Low or Intermediate Risk

Presenter: Stephen Grant Worthley

October 25, 2025

Presentation TCT 2025

Valve Performance of Self-Expanding vs. Balloon-Expandable TAVR in Patients with a Small Aortic Annulus: Five-Year Results From the OCEAN-TAVI Registry

Presenter: Fumiaki Yashima

October 25, 2025

Presentation TCT 2025

Early Outcomes of Redo-TAVI With SAPIEN Platform in a Real-World Prospective Cohort: The ReTAVI Registry

Presenter: Giuseppe Tarantini

October 25, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

Presentation TCT 2024

The Rise of AHA Target: Aortic Stenosis – Applying Quality Improvement Upstream of the Procedure (in partnership with the American Heart Association)

Presenter: Brian Lindman

October 30, 2024

Presentation TCT 2024

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

Presenter: Didier Tchetche

October 29, 2024

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

L.A. McKeown

October 28, 2024

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

News Conference News TCT 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Yael L. Maxwell

November 02, 2023

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

L.A. McKeown

October 27, 2023

Presentation TCT 2023

Position 3: Initial TAVR

Presenter: Mathew Williams

October 25, 2023

Presentation TCT 2023

Importance of Patient Reported Outcomes

Presenter: David Cohen

October 24, 2023

Presentation TCT 2023

An Echo Deep Dive of the PARTNER 5-Year Study

Presenter: Philippe Pibarot

October 24, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Presentation TCT 2023

Important Secondary Endpoints From the PARTNER 3 5-YEAR STUDY

Presenter: Raj Makkar

October 24, 2023

Advertisement

Cath Lab Economics 101: Understanding RVUs, DRGs, and Payer Trends

Predictors of a Positive Treadmill Stress Test in Patients with Asymptomatic Severe Aortic Stenosis: Insights from the EARLY TAVR Treadmill Registry

Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Women with Severe Aortic Stenosis: The RHEIA Trial

Thirty-Day and One-Year Outcomes of the Navitor TAVR System in Patients with Low or Intermediate Risk

Valve Performance of Self-Expanding vs. Balloon-Expandable TAVR in Patients with a Small Aortic Annulus: Five-Year Results From the OCEAN-TAVI Registry

Early Outcomes of Redo-TAVI With SAPIEN Platform in a Real-World Prospective Cohort: The ReTAVI Registry

What’s Going to Be Hot at TCT 2025

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

The Rise of AHA Target: Aortic Stenosis – Applying Quality Improvement Upstream of the Procedure (in partnership with the American Heart Association)

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

What’s Going to Be Big at TCT 2024?

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

Position 3: Initial TAVR

Importance of Patient Reported Outcomes

An Echo Deep Dive of the PARTNER 5-Year Study

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Important Secondary Endpoints From the PARTNER 3 5-YEAR STUDY

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content